Cargando…

Trends in Light and Temperature Sensitivity Recommendations among Licensed Biotechnology Drug Products

PURPOSE: Inherent structural and functional properties of biotechnology-derived therapeutic biologics make them susceptible to light- and temperature-induced degradation and consequently can influence their quality. Photosensitivity of therapeutic proteins continues to be examined, but the commonali...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Jennifer J., Pritts, Jordan D., Ngo, Mai, Estoll, Corey R., Rao, V. Ashutosh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338390/
https://www.ncbi.nlm.nih.gov/pubmed/37022633
http://dx.doi.org/10.1007/s11095-023-03494-0
_version_ 1785071618142240768
author Kim, Jennifer J.
Pritts, Jordan D.
Ngo, Mai
Estoll, Corey R.
Rao, V. Ashutosh
author_facet Kim, Jennifer J.
Pritts, Jordan D.
Ngo, Mai
Estoll, Corey R.
Rao, V. Ashutosh
author_sort Kim, Jennifer J.
collection PubMed
description PURPOSE: Inherent structural and functional properties of biotechnology-derived therapeutic biologics make them susceptible to light- and temperature-induced degradation and consequently can influence their quality. Photosensitivity of therapeutic proteins continues to be examined, but the commonalities and trends of storage conditions and information about light and temperature sensitivity among currently licensed therapeutic proteins has not been previously surveyed. METHODS: Using a comprehensive and relational database approach, we conducted a scientific survey of all licensed biotechnology-derived drug products with the goal of providing evidence-based information about recommended storage conditions of formulations sorted by light- and temperature-related attributes as described for each product at licensure. RESULTS: We report the prevalence of indications for light and temperature sensitivity in formulations categorized by their presentation type, number of doses, container type, dosage form and active molecule type. We also report the storage temperature range across formulations and diluents for reconstitution and dilution. Formulations with excipients that potentially facilitate light-induced and thermal degradation were also noted. CONCLUSIONS: The result of our analysis indicates that light and temperature sensitivity are prevalent across therapeutic protein formulations. However, when a formulation is reconstituted or diluted, both light and temperature sensitivity are less clear. In addition, light and temperature sensitivity are more well defined in liquid formulations than lyophilized powder formulations, and more well defined in products manufactured in autoinjectors, prefilled-syringes, and pens than products in vials. Overall, our report provides a data-driven summary of storage conditions among therapeutic protein formulations to support the development of future biologic drug products.
format Online
Article
Text
id pubmed-10338390
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-103383902023-07-14 Trends in Light and Temperature Sensitivity Recommendations among Licensed Biotechnology Drug Products Kim, Jennifer J. Pritts, Jordan D. Ngo, Mai Estoll, Corey R. Rao, V. Ashutosh Pharm Res Original Research Article PURPOSE: Inherent structural and functional properties of biotechnology-derived therapeutic biologics make them susceptible to light- and temperature-induced degradation and consequently can influence their quality. Photosensitivity of therapeutic proteins continues to be examined, but the commonalities and trends of storage conditions and information about light and temperature sensitivity among currently licensed therapeutic proteins has not been previously surveyed. METHODS: Using a comprehensive and relational database approach, we conducted a scientific survey of all licensed biotechnology-derived drug products with the goal of providing evidence-based information about recommended storage conditions of formulations sorted by light- and temperature-related attributes as described for each product at licensure. RESULTS: We report the prevalence of indications for light and temperature sensitivity in formulations categorized by their presentation type, number of doses, container type, dosage form and active molecule type. We also report the storage temperature range across formulations and diluents for reconstitution and dilution. Formulations with excipients that potentially facilitate light-induced and thermal degradation were also noted. CONCLUSIONS: The result of our analysis indicates that light and temperature sensitivity are prevalent across therapeutic protein formulations. However, when a formulation is reconstituted or diluted, both light and temperature sensitivity are less clear. In addition, light and temperature sensitivity are more well defined in liquid formulations than lyophilized powder formulations, and more well defined in products manufactured in autoinjectors, prefilled-syringes, and pens than products in vials. Overall, our report provides a data-driven summary of storage conditions among therapeutic protein formulations to support the development of future biologic drug products. Springer US 2023-04-06 2023 /pmc/articles/PMC10338390/ /pubmed/37022633 http://dx.doi.org/10.1007/s11095-023-03494-0 Text en © This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Research Article
Kim, Jennifer J.
Pritts, Jordan D.
Ngo, Mai
Estoll, Corey R.
Rao, V. Ashutosh
Trends in Light and Temperature Sensitivity Recommendations among Licensed Biotechnology Drug Products
title Trends in Light and Temperature Sensitivity Recommendations among Licensed Biotechnology Drug Products
title_full Trends in Light and Temperature Sensitivity Recommendations among Licensed Biotechnology Drug Products
title_fullStr Trends in Light and Temperature Sensitivity Recommendations among Licensed Biotechnology Drug Products
title_full_unstemmed Trends in Light and Temperature Sensitivity Recommendations among Licensed Biotechnology Drug Products
title_short Trends in Light and Temperature Sensitivity Recommendations among Licensed Biotechnology Drug Products
title_sort trends in light and temperature sensitivity recommendations among licensed biotechnology drug products
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338390/
https://www.ncbi.nlm.nih.gov/pubmed/37022633
http://dx.doi.org/10.1007/s11095-023-03494-0
work_keys_str_mv AT kimjenniferj trendsinlightandtemperaturesensitivityrecommendationsamonglicensedbiotechnologydrugproducts
AT prittsjordand trendsinlightandtemperaturesensitivityrecommendationsamonglicensedbiotechnologydrugproducts
AT ngomai trendsinlightandtemperaturesensitivityrecommendationsamonglicensedbiotechnologydrugproducts
AT estollcoreyr trendsinlightandtemperaturesensitivityrecommendationsamonglicensedbiotechnologydrugproducts
AT raovashutosh trendsinlightandtemperaturesensitivityrecommendationsamonglicensedbiotechnologydrugproducts